Get the Stockscreener App
73.22
2.94%
2.09
After Hours:
73.22
Edwards Lifesciences Corp stock is traded at $73.22, with a volume of 4.13M.
It is up +2.94% in the last 24 hours and down -1.37% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
See More
Previous Close:
$71.13
Open:
$73.11
24h Volume:
4.13M
Relative Volume:
0.87
Market Cap:
$43.46B
Revenue:
$6.60B
Net Income/Loss:
$4.16B
P/E Ratio:
10.57
EPS:
6.93
Net Cash Flow:
$490.10M
1W Performance:
+6.22%
1M Performance:
-1.37%
6M Performance:
+15.05%
1Y Performance:
-0.92%
1-Day Range:
$72.63
$73.88
1-Week Range:
$68.40
$73.88
52-Week Range:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
73.22 | 43.46B | 6.60B | 4.16B | 490.10M | 6.93 |
|
ABT
Abbott Laboratories
|
128.81 | 223.55B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
103.05 | 152.39B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
390.43 | 149.22B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
91.99 | 118.43B | 33.00B | 4.29B | 5.50B | 3.27 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
11 Analysts Have This To Say About Edwards Lifesciences - Benzinga
Edwards Lifesciences (NYSE:EW) Rating Increased to Buy at Stifel Nicolaus - MarketBeat
Swedbank AB Has $57.78 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
This Coca-Cola Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Stifel Upgrades Edwards Lifesciences to Buy From Hold, Adjusts Price Target to $90 From $75 - Marketscreener.com
Stifel raises Edwards Lifesciences stock to buy, target to $90 - Investing.com
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
KBC Group NV Sells 248,320 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Cuts Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO - Orange County Business Journal
Agree To Purchase Edwards Lifesciences At $55, Earn 7.8% Using Options - Nasdaq
Baldwin Wealth Partners LLC MA Reduces Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
United Asset Strategies Inc. Has $12.45 Million Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Stonehage Fleming Financial Services Holdings Ltd - MarketBeat
CX Institutional Buys New Stake in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Harrell Investment Partners LLC Sells 12,378 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Smart Money Is Betting Big In Edwards Lifesciences Options - Benzinga
Manitou Investment Management Ltd. Increases Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Inspire Investing LLC - MarketBeat
What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing? - Yahoo Finance
Wendell David Associates Inc. Trims Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Nisa Investment Advisors LLC Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by UMB Bank n.a. - MarketBeat
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock - MSN
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
1,478,989 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Seilern Investment Management Ltd - MarketBeat
Gateway Investment Advisers LLC Acquires 5,726 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Sees Significant Growth in Short Interest - MarketBeat
Boston Common Asset Management LLC Lowers Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
65,442 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Avanza Fonder AB - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) VP Sells $34,380.00 in Stock - MarketBeat
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock By Investing.com - Investing.com Canada
Wolfe Research Downgrades Edwards Lifesciences (EW) - MSN
Do You Believe in the Growth Prospects of Edwards Lifesciences Corporation (EW)? - MSN
West Coast Financial LLC Has $9.87 Million Stake in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Wolfe Research cuts Edwards Lifesciences stock rating to Underperform - MSN
Declining Stock and Solid Fundamentals: Is The Market Wrong About Edwards Lifesciences Corporation (NYSE:EW)? - Yahoo Finance
Wolfe Research Downgrades Edwards Lifesciences (NYSE:EW) to Underperform - MarketBeat
Should Edwards Lifesciences Stock Stay in Your Portfolio Now? - Yahoo Finance
Meril successful at EPO against Edwards Lifesciences in heart-valve battle - JUVE Patent
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Assenagon Asset Management S.A. Buys 3,506,886 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST Purchases 300,000 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences price target raised to $74 from $72 at Bernstein - MSN
Edwards Lifesciences’ Q4 2024 Earnings: What to Expect - Nasdaq
Edwards Lifesciences’ Q4 2024 Earnings: What To Expect - Barchart
Edwards Lifesciences Co. (NYSE:EW) Receives $79.40 Consensus Target Price from Analysts - MarketBeat
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Stock Price | EW Stock Quote, News, and History - Markets Insider
Brain Ischemia Market grow at CAGR of 7.6% Growth, Reaching $1,622 million by 2032 Globally - GlobeNewswire Inc.
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):